This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Email citation

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

. 2024 Oct;177(10):1440-1442.

doi: 10.7326/ANNALS-24-00308. Epub 2024 Aug 27.

Estimating New Eligibility and Maximum Costs of Expanded Medicare Coverage of Semaglutide for Cardiovascular Risk Prevention

Alexander Chaitoff¹, Liam Bendicksen², William B Feldman³, Alexander R Zheutlin⁴, Hussain S Lalani⁵

Affiliations

Affiliations

¹ Center for Healthcare Delivery Sciences, Division of Pharmacoepidemiology, Department of Medicine, Brigham and Women's Hospital, Boston; and Harvard Medical School, Boston, Massachusetts.
² Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts.
³ Harvard Medical School, Boston; Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Boston; and Division of Pulmonary and Critical Care Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts.
⁴ Division of Cardiology, Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, Illinois.
⁵ Harvard Medical School, Boston; and Division of General Internal Medicine and Primary Care, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts.

PMID: 39186788
DOI: 10.7326/ANNALS-24-00308

Estimating New Eligibility and Maximum Costs of Expanded Medicare Coverage of Semaglutide for Cardiovascular Risk Prevention

Alexander Chaitoff et al. Ann Intern Med. 2024 Oct.

. 2024 Oct;177(10):1440-1442.

doi: 10.7326/ANNALS-24-00308. Epub 2024 Aug 27.

Authors

Alexander Chaitoff¹, Liam Bendicksen², William B Feldman³, Alexander R Zheutlin⁴, Hussain S Lalani⁵

Affiliations

¹ Center for Healthcare Delivery Sciences, Division of Pharmacoepidemiology, Department of Medicine, Brigham and Women's Hospital, Boston; and Harvard Medical School, Boston, Massachusetts.
² Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts.
³ Harvard Medical School, Boston; Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Boston; and Division of Pulmonary and Critical Care Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts.
⁴ Division of Cardiology, Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, Illinois.
⁵ Harvard Medical School, Boston; and Division of General Internal Medicine and Primary Care, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts.

PMID: 39186788
DOI: 10.7326/ANNALS-24-00308

No abstract available

PubMed Disclaimer

Conflict of interest statement

Disclosures: Disclosure forms are available with the article online.

Similar articles

Semaglutide's CVD indication could cost US Medicare $145bn extra a year.
Mahase E. Mahase E. BMJ. 2024 Aug 28;386:q1878. doi: 10.1136/bmj.q1878. BMJ. 2024. PMID: 39197936 No abstract available.
Prescription Fills for Semaglutide Products by Payment Method.
Scannell C, Romley J, Myerson R, Goldman D, Qato DM. Scannell C, et al. JAMA Health Forum. 2024 Aug 2;5(8):e242026. doi: 10.1001/jamahealthforum.2024.2026. JAMA Health Forum. 2024. PMID: 39093590 Free PMC article.
Oral semaglutide versus injectable glucagon-like peptide-1 receptor agonists: a cost of control analysis.
Hansen BB, Nuhoho S, Ali SN, Dang-Tan T, Valentine WJ, Malkin SJP, Hunt B. Hansen BB, et al. J Med Econ. 2020 Jun;23(6):650-658. doi: 10.1080/13696998.2020.1722678. Epub 2020 Feb 7. J Med Econ. 2020. PMID: 31990244
Efficacy and safety of once-weekly semaglutide for the treatment of type 2 diabetes.
Tan X, Cao X, Zhou M, Zou P, Hu J. Tan X, et al. Expert Opin Investig Drugs. 2017 Sep;26(9):1083-1089. doi: 10.1080/13543784.2017.1360274. Epub 2017 Aug 2. Expert Opin Investig Drugs. 2017. PMID: 28741970 Review.
Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 1-7 trials.
Aroda VR, Ahmann A, Cariou B, Chow F, Davies MJ, Jódar E, Mehta R, Woo V, Lingvay I. Aroda VR, et al. Diabetes Metab. 2019 Oct;45(5):409-418. doi: 10.1016/j.diabet.2018.12.001. Epub 2019 Jan 4. Diabetes Metab. 2019. PMID: 30615985 Review.

See all similar articles

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Atypon
- Ovid Technologies, Inc.